The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer

Redox Biology

Volumn 1, Issue 1, 2013, Pages 45-49

  Kansanen, Emilia ^a   Kuosmanen, Suvi M ^a   Leinonen, Hanna ^a   Levonenn, Anna Liisa ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Antioxidant response element; Cancer; Gene therapy; Keap 1; Nrf2

Indexed keywords

BRUSATOL; CISPLATIN; DOXORUBICIN; GANCICLOVIR; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LENTIVIRUS VECTOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; SMALL INTERFERING RNA; THYMIDINE KINASE; TRANSCRIPTION FACTOR NRF2; CYTOSKELETON PROTEIN; SIGNAL PEPTIDE;

ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL KILLING; CELL PROTECTION; GENE EXPRESSION; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; SUICIDE GENE THERAPY; ANIMAL; HUMAN; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; CYTOSKELETAL PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; NF-E2-RELATED FACTOR 2;

EID: 84878785993     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2012.10.001     Document Type: Review

References (17)

1. E. Kansanen, H.-K. Jyrkkänen, A.-L. Levonen, Activation of stress signaling pathways by electrophilic oxidized and nitrated lipids, Free Radical Biology and Medicine 52 (2012) 973-982.
2. E. Kansanen, A.M. Kivelä, A.-L. Levonen, Regulation of Nrf2-dependent gene expression by 15-deoxy-Delta12,14-prostaglandin J2, Free Radical Biology and Medicine 47 (2009) 1310-1317.
3. K. Taguchi, H. Motohashi, M. Yamamoto, Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution, Genes Cells 16 (2011) 123-140.
4. M.B. Sporn, K.T. Liby, NRF2 and cancer: the good, the bad and the importance of context, Nature Reviews Cancer 12 (2012) 564-571.
5. G.M. DeNicola, F.A. Karreth, T.J. Humpton, A. Gopinathan, C. Wei, K. Frese, D. Mangal, K.H. Yu, C.J. Yeo, E.S. Calhoun, F. Scrimieri, J.M. Winter, R.H. Hruban, C. Iacobuzio-Donahue, S.E. Kern, I.A. Blair, D.A. Tuveson, Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis, Nature 475 (2011) 106-109.
6. N. Hanada, T. Takahata, Q. Zhou, X. Ye, R. Sun, J. Itoh, A. Ishiguro, H. Kijima, J. Mimura, K. Itoh, S. Fukuda, Y. Saijo, Methylation of the KEAP1 gene promoter region in human colorectal cancer, BMC Cancer 12 (2012) 66.
7. P. Zhang, A. Singh, S. Yegnasubramanian, D. Esopi, P. Kombairaju, M. Bodas, H. Wu, S.G. Bova, S. Biswal, Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresis-tance and promotes tumor growth, Molecular Cancer Therapeutics 9 (2010) 336-346.
8. J. Adam, E. Hatipoglu, L. O'Flaherty, N. Ternette, N. Sahgal, H. Lockstone, D. Baban, E. Nye, G.W. Stamp, K. Wolhuter, M. Stevens, R. Fischer, P. Carmeliet, P.H. Maxwell, C.W. Pugh, N. Frizzell, T. Soga, B.M. Kessler, M. El-Bahrawy, P.J. Ratcliffe, et al., Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling, Cancer Cell 20 (2011) 524-537.
9. A. Ooi, J.-C. Wong, D. Petillo, D. Roossien, V. Perrier-Trudova, D. Whitten, B.W.H. Min, M.-H. Tan, Z. Zhang, X.J. Yang, M. Zhou, B. Gardie, V. Molinié, S. Richard, P.H. Tan, B.T. Teh, K.A. Furge, An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carci
10. Q. Ma, X. He, Molecular basis of electrophilic and oxidative defense: promises and perils of nrf2, Pharmacological Reviews 64 (2012) 1055-1081.
11. Y. Mitsuishi, K. Taguchi, Y. Kawatani, T. Shibata, T. Nukiwa, H. Aburatani, M. Yamamoto, H. Motohashi, Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming, Cancer Cell 22 (2012) 66-79.
12. D. Ren, N.F. Villeneuve, T. Jiang, T. Wu, A. Lau, H.A. Toppin, D.D. Zhang, Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism, Proceedings of the National Academy of Sciences USA 108 (2011) 1433-1438.
13. S. Chowdhry, Y. Zhang, M. McMahon, C. Sutherland, A. Cuadrado, J.D. Hayes, Nrf2 is controlled by two distinct b-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity, Oncogene (2012).
14. A. Singh, S. Boldin-Adamsky, R.K. Thimmulappa, S.K. Rath, H. Ashush, J. Coulter, A. Blackford, S.N. Goodman, F. Bunz, W.H. Watson, E. Gabrielson, E. Feinstein, S. Biswal, RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy, Cancer Research 68 (2008) 7975-7984.
15. H. Hurttila, J.K. Koponen, E. Kansanen, H.-K. Jyrkkänen, A. Kivelä, R. Kylätie, S. Ylä-Herttuala, A.-L. Levonen, Oxidative stress-inducible lentiviral vectors for gene therapy, Gene Therapy 15 (2008) 1271-1279.
16. H.M. Leinonen, A.-K. Ruotsalainen, A.-M. Määttä, H.M. Laitinen, S.M. Kuosmanen, E. Kansanen, J.T. Pikkarainen, J.P. Lappalainen, H. Samaranayake, H.P. Lesch, M.U. Kaikkonen, S. Ylä-Herttuala, A.-L. Levonen, Oxidative stress-regulated lentiviral TK/GCV gene therapy for lung cancer treatment, Cancer Research 23 (2012) 6227-6235.
17. F.L. Moolten, Tumor chemosensitivity conferred by inserted herpes thymi-dine kinase genes: paradigm for a prospective cancer control strategy, Cancer Research 46 (1986) 5276-5281.